Preliminary clinical evaluation of Portulaca oleraceae seed on treatment of dyslipidemia in adolescents

Clinical evaluation of Portulaca oleraceae seed in comparision with placebo on treatment of dyslipidemia in adolescents between 12-18 years old

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109122306N4

Enrollment

Registered

2012-07-26

Start date

2011-05-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia. Hyperlipidaemia,unspecified

Interventions

Intervention 1: Portulaca oleraceae seed powder in 500 mg capsules thrice a day for one month. Intervention 2: placebo powder in 500mg capsules thrice a day for one month.

Treatment - Drugs

Placebo

Portulaca oleraceae seed powder in 500 mg capsules thrice a day for one month

placebo powder in 500mg capsules thrice a day for one month

Eligibility

Sex/Gender

All

Age

12 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1)adolescents between 12 to 18 years old that have at least one of these criteria: a: triglyceride more than 90 percentile b: total cholesterol more than 90 percentile c: LDL more than 90 percentile d:HDL less than 10 percentile 2) Not using tobacco 3) No history of alcohol consumption or drug abuse 4) No history of metabolic diseases like diabetes, thyroid gland dysfunction, nephrotic syndrome, chronic pancreatitis, liver and gall bladder diseases that affects lipid profiles 5) No use of drugs which affect lipid profiles like statins and hormonal pills like estrogens, progestrones and oral contraceptives. Exclusion criteria: 1) Lack of patient’s compliance with drug regimens at least for one week. 2) Pregnancy and lactation 3) Drug sensitivity 4) Suffering from any diseases which interact with lipid profiles 5) Intake of any kind of drugs or other compounds lowering lipid profile like corticosteroids, androgens, estrogenes, progestines, thiazides, beta blockers and thyroid hormones

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HDL cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;LDL cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Triglyceride. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Total cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.	—

Measure

Time frame

HDL cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;LDL cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Triglyceride. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.;Total cholestrol. Timepoint: Before intervention, one month after intervention. Method of measurement: mg/dl through using laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi jelokhanian

Isfahan University of Medical Sciences

hadi_jelokhanian@yahoo.com+98 31 1336 8589

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026